Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments: 2021-2025

Historic Cash & Current Investments for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $529.3 million.

  • Kiniksa Pharmaceuticals International's Cash & Current Investments rose 51.16% to $529.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 33.47%. This contributed to the annual value of $243.6 million for FY2024, which is 18.05% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Cash & Current Investments of $529.3 million as of Q3 2025, which was up 24.99% from $423.5 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Cash & Current Investments' 5-year high stood at $529.3 million during Q3 2025, with a 5-year trough of $182.1 million in Q2 2022.
  • Moreover, its 3-year median value for Cash & Current Investments was $294.4 million (2023), whereas its average is $326.6 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first slumped by 44.19% in 2022, then soared by 51.16% in 2025.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Cash & Current Investments stood at $182.2 million in 2021, then climbed by 4.61% to $190.6 million in 2022, then grew by 8.27% to $206.4 million in 2023, then increased by 18.05% to $243.6 million in 2024, then spiked by 51.16% to $529.3 million in 2025.
  • Its last three reported values are $529.3 million in Q3 2025, $423.5 million for Q2 2025, and $379.5 million during Q1 2025.